Drugs / NAL ER
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07036029 | Aug 2025 → Jun 2026 overdue | idiopathic pulmonary fibrosis | Trevi Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07015398 | Jun → Sep 2025 | — | Trevi Therapeutics | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05962151 | Nov 2023 → Jan 2025 | respiratory system disorder | Trevi Therapeutics | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAL ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07015398 ↗ |
| Route | Oral | “Oral tablets” NCT05962151 ↗ |